Home|Journals|Articles by Year|Audio Abstracts

Original Article

In Vitro Antiproliferative effect of Aqueous extract of Solanum macranthum Fruits on MDA-MB-231 Tripple Negative Breast Cancer Cell Line

Vishal U. Kalebar, Joy H. Hoskeri, Shivaprakash V. Hiremath, Murigendra B. Hiremath.

Cited by 2 Articles

The current investigation focused on the antiproliferative effects of the S.macranthum aqueous fruits extract against the human breast cancer cell line MDA-MB-23 in vitro. Phytochemical analysis of the S.macranthum aqueous fruits extract was performed and the phytoconstituents found positive are alkaloids, phenols and saponins. Quantitative analysis of the total alkaloid and phenol was determined using gravimetric analysis and Folins-phenols reagent method respectively. The total alkaloid present was estimated to be 7.58% and total phenol of 158.774 mg/GAC. The cytotoxicity of S.macranthum aqueous fruits extract was screened using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay and camptothecin was used as reference drug. At the concentration of 500g/ml the aqueous extract could potentially inhibit the growth of the MDA-MB-231 cell line in vitro reaching 19%, and the IC50 value was calculated to be 325.59g/ml. Thus signifying that aqueous extract of the S.macranthum fruits tends to possess potential anticancer property.

Key words: S.macranthum, aqueous extract, Breast cancer, MTT assay

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.